Editas Medicine Announces Third Quarter 2023 Results Conference Call and Upcoming Investor Events
October 27, 2023 07:00 ET
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., Oct. 27, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it will host a conference call and webcast...
Editas Medicine Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for EDIT-301 for the Treatment of Severe Sickle Cell Disease
October 16, 2023 08:00 ET
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that the U.S. Food and Drug Administration (FDA)...
Editas Medicine Reports Inducement Grants to New Chief Commercial and Strategy Officer
September 25, 2023 16:30 ET
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the grant of an inducement award to the Company’s...
Editas Medicine Strengthens Executive Leadership Team with Appointment of Caren Deardorf as Chief Commercial and Strategy Officer
September 25, 2023 09:00 ET
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the appointment of Caren Deardorf as the Company’s...
Editas Medicine Announces Upcoming Investor Events
August 30, 2023 09:00 ET
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that management will participate in the following...
Editas Medicine Announces Second Quarter 2023 Results and Business Updates
August 02, 2023 07:00 ET
|
Editas Medicine, Inc.
On track to dose 20 total patients in the EDIT-301 RUBY trial for SCD and provide a clinical update by year-end Commenced parallel patient dosing in the EDIT-301 EDITHAL trial for TDT and on...
Editas Medicine and Azzur Group Expand Partnership to Accelerate Editas’ Manufacturing Capabilities for Advancing the EDIT-301 Program Through Approval to Commercialization
July 27, 2023 09:00 ET
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., and DEVENS, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, and Azzur Cleanrooms on Demand™ (COD), an Azzur...
Editas Medicine Announces Second Quarter 2023 Results Conference Call and Corporate Update
July 26, 2023 07:00 ET
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., July 26, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it will host a conference call and webcast...
Editas Medicine Reports Inducement Grant to New Chief Scientific Officer
July 25, 2023 08:00 ET
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., July 25, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced the grant of an inducement award to the Company’s...
Editas Medicine Strengthens Executive Leadership Team with Appointment of Linda C. Burkly, Ph.D., as Chief Scientific Officer
July 24, 2023 07:00 ET
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., July 24, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the appointment of Linda C. Burkly, Ph.D., as the...